Results 21 to 30 of about 92,350 (272)

Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19

open access: yesBMJ Open, 2022
Objectives Assess the association between tocilizumab administration and clinical outcomes among mechanically ventilated patients with COVID-19 pneumonia.Design Retrospective cohort study.Setting Large integrated health system with 9 million members in ...
Sara Y Tartof   +11 more
doaj   +1 more source

Tocilizumab [PDF]

open access: yesmAbs, 2009
Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is ...
openaire   +3 more sources

Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients

open access: yesInternational Journal of Infectious Diseases, 2021
Objectives: The purpose of this study is to evaluate clinical outcomes in patients with critical COVID-19 pneumonia requiring invasive mechanical ventilation who were treated with tocilizumab Design: Single-center retrospective cohort study Setting ...
Matthew J. Fisher   +4 more
doaj   +1 more source

Tocilizumab Reduces Vasospasms, Neuronal Cell Death, and Microclot Formation in a Rabbit Model of Subarachnoid Hemorrhage. [PDF]

open access: yes, 2021
Early brain injury (EBI), delayed cerebral vasospasm (DCVS), and delayed cerebral ischemia (DCI) are common complications of subarachnoid hemorrhage (SAH).
Marbacher, Serge   +25 more
core   +1 more source

Impact of three consecutive intravenous doses of tocilizumab in severe COVID-19 pneumonia: a retrospective cohort study

open access: yesMicrobes, Infection and Chemotherapy, 2021
Background. Acute respiratory distress syndrome (ARDS) in severe COVID-19 pneumonia is mostly responsible for high mortality rate. Tocilizumab, an interleukin-6 (IL-6) inhibitors, down-regulates the progression of cytokine storm leading to ARDS ...
Raihan Rabbani   +3 more
doaj   +1 more source

Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2

open access: yesCritical Care Explorations, 2021
Objectives:. To identify the most efficacious timing for tocilizumab administration in critically ill patients infected with severe acute respiratory syndrome coronavirus-2. Design:. Observational multicenter cohort study. Setting:.
Russell M. Petrak, MD   +8 more
doaj   +1 more source

Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study

open access: yesAntibiotics, 2022
(1) Background: The efficacy of tocilizumab in COVID-19 has been doubted. The study aimed to investigate factors affecting disease stability and response to tocilizumab among severe COVID-19 patients.
Wael Hafez, Ahmed Abdelrahman
doaj   +1 more source

CU Tocilizumab Colombia

open access: yes, 2022
CU Tocilizumab ...
Jefferson Buendia
core   +1 more source

Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis

open access: yesКачественная клиническая практика, 2020
Rationale. Rheumatoid arthritis (RA) and systemic juvenile arthritis (sJA) are the most frequent rheumatic diseases in adults and adolescents, consequently. Biologics disease modifying antirheumatic drugs (bDMARDs) are eff ective in treatment of RA and s
A. S. Kolbin   +4 more
doaj   +1 more source

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome

open access: yesScientific Reports, 2023
Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal antibodies as well as anti-tumor necrosis factor are considered promising treatments for COVID-19.
Neven Mohamed Sarhan   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy